Literature DB >> 30072064

World Health Organization 2016 Classification of Central Nervous System Tumors.

Phedias Diamandis1, Kenneth Aldape2.   

Abstract

The recent update of the World Health Organization (WHO) classification of tumors of the central nervous system represents a paradigm shift. Previous iterations of the classification relied on morphologic features for classification. In the 2016 update, the definitions of specific neoplastic entities tumors now include precise molecularly defined entities. This article discusses this paradigm shift, and focuses on the refinements in classification criteria, relations to previous editions, and their implication to neuropathology and neuro-oncology practice. The authors distinguish the criteria that were used to determine why molecular changes were included.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain tumors; Classification; Molecular pathology; Neuropathology; World Health Organization

Mesh:

Year:  2018        PMID: 30072064     DOI: 10.1016/j.ncl.2018.04.003

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  24 in total

1.  ERK inhibition in glioblastoma is associated with autophagy activation and tumorigenesis suppression.

Authors:  Kang Yang; Lan Luan; Xinyu Li; Xu Sun; Jian Yin
Journal:  J Neurooncol       Date:  2021-11-19       Impact factor: 4.130

2.  IFN-γ induces PD-L1 through p38/JNK/ERK signaling pathways and counteracts the tumor promoting effect mediated by PD-L1 in Glioblastoma.

Authors:  Huafang Jia; Xiaoli Xie; Long Wang; Lijuan Wang; Fengyuan Che
Journal:  Comput Intell Neurosci       Date:  2022-06-29

3.  Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.

Authors:  Stewart Goldman; Ian F Pollack; Regina I Jakacki; Catherine A Billups; Tina Y Poussaint; Adekunle M Adesina; Ashok Panigrahy; Donald W Parsons; Alberto Broniscer; Giles W Robinson; Nathan J Robison; Sonia Partap; Lindsay B Kilburn; Arzu Onar-Thomas; Ira J Dunkel; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

4.  Pathology-proven extradural ("distant") metastases of gliomas in adults in the Netherlands between 1971 and 2018: a systematic case series.

Authors:  Sanne J den Hartog; Anja van der Kolk; Annette Bruggink; Tatjana Seute; Pieter Wesseling; Joyce Wilbers
Journal:  Neurooncol Pract       Date:  2021-01-22

5.  Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma.

Authors:  Congxiao Wang; Chao Liu; Jun Chen; Han Jiang; Wei Zhang; Lili Yang; Xueda Li; Zixiang Li; Lijing Peng; Xiaokun Hu; Peng Sun
Journal:  BMC Cancer       Date:  2022-04-12       Impact factor: 4.430

6.  H3 K27M-mutant glioma: clinical characteristics and outcomes.

Authors:  Tianwei Wang; Yongming Qiu; Lili Liang; Erliang Zheng; Ting Gao
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

7.  CDK5 Knockdown inhibits proliferation and induces apoptosis and Cell Cycle Arrest in Human Glioblastoma.

Authors:  Yan Zhou; Xuan Wang; Peng Lv; Hao Yu; Xiaobing Jiang
Journal:  J Cancer       Date:  2021-05-10       Impact factor: 4.207

8.  Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile.

Authors:  Krinio Giannikou; Zachary Zhu; Jaegil Kim; Kellen D Winden; Magdalena E Tyburczy; David Marron; Joel S Parker; Zachary Hebert; Anika Bongaarts; Len Taing; Henry W Long; William V Pisano; Sanda Alexandrescu; Brianna Godlewski; Mark Nellist; Katarzyna Kotulska; Sergiusz Jozwiak; Marcin Roszkowski; Marek Mandera; Elizabeth A Thiele; Hart Lidov; Gad Getz; Orrin Devinsky; Michael S Lawrence; Keith L Ligon; David W Ellison; Mustafa Sahin; Eleonora Aronica; David M Meredith; David J Kwiatkowski
Journal:  Mod Pathol       Date:  2020-10-13       Impact factor: 8.209

9.  LINC01207 Predicts Poor Prognosis and Suppresses Cell Growth and Metastasis via Regulating GSK-3β/β-Catenin Signaling Pathway in Malignant Glioma.

Authors:  Dapeng Chi; Wei Zhang; Yulong Jia; Damin Cong; Kui Yu; Shaoshan Hu
Journal:  Med Sci Monit       Date:  2020-06-13

10.  High expression of cluster of differentiation 276 indicates poor prognosis in glioma.

Authors:  Linchen Li; Min Zhang; Dengna Zhu; Xinjun Wang
Journal:  Clin Med Insights Oncol       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.